Abstract
To “stun” has been defined in several ways. The Webster dictionary provides synonyms of “to make senseless,” “to daze or stupefy,” or “to shock deeply.” The adjective form also means excellent or attractive. None of these definitions accurately represent “stunning” in relation to the treatment of thyroid cancer. Stunning entails that a diagnostic dose of radioiodine (131I) can sufficiently damage the thyroid, making follicular cells incapable of trapping subsequent therapeutic 131I (1,2). It is true that some of us were stupefied when the concept was first presented. Early reports implied that there would be no uptake of therapy. Thus, when a pretreatment diagnostic scan was compared to a posttherapy scan, the latter showed absence of uptake at one or more sites. Subsequently, the term was expanded to include the possibility that the percentage uptake of the therapeutic dose would be less than that of the prior diagnostic scintiscan, i.e., a quantitatively different finding. Lastly, the term “stunning” was expanded to include a poorer outcome after treatment than when there was no diagnostic dose prescribed or when an alternative imaging agent, such as 123I, is used in place of 131I (3,4).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49–54.
Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7:277–280.
Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6–9.
Gerard SK. Whole-body thyroid tumor 123I scintigraphy. J Nucl Med 2003; 44:852.
Allman KC. Thyroid stunning revisited. J Nucl Med 2003; 44:1194.
Coakley A. Thyroid stunning. Eur J Nucl Med 1998; 25:203–204.
Brenner W. Is thyroid stunning a real phenomenon or just fiction? J Nucl Med 2002; 43:835–836.
Hurley JR. Management of thyroid cancer: radioiodine ablation, “stunning,” and treatment of thyroglobulin-positive, (131)I scannegative patients. Endocr Pract 2000; 6:401–406.
Medvedec M. Thyroid stunning. J Nucl Med 2001; 42:1129–1131.
Diehl M, Grunwald F. Stunning after tracer dosimetry. J Nucl Med 2001; 42:1129.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.
Nemec J, Röhling S, Zamrazil V, Pohunková D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20:92–97.
Waxman A, Ramana L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: Concise communication. J Nucl Med 1981; 22:861–865.
Spies W, Wojtowicz CH, Spies SH, et al. Value of post-therapy wholebody I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 1989; 14:793–800.
Pacini F, Lippi L, Formica M, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum-thyroglobulin levels. J Nucl Med 1987; 28:1888–1891.
Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. 1997; 7:273–276.
Pineda J, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488–1492.
Rawson R, Rall JE, Peacock W. Limitations and indications in the treatment of thyroid cancer with radioactive iodine. J Clin Endocrinol Metab 1951; 11:1128–1142.
Cholewinski SP, Yoo KS, Klieger PS, O’Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 2000; 41:1198–1202.
Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573–577.
Bajen M, Mane S, Munoz A, Garcia JR. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med 2000; 41:2038–2042.
Yeung H, Humm JL, Larson SM. Thyroid stunning. J Nucl Med 2001; 42:1130–1131.
McDougall IR. 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e., it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505–512.
Cohen J, Kalinyak JE, McDougall IR. Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans. Nucl Med Commun 2004; 25:129–134.
Hu YH, Wang PW, Wang ST, et al. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation. Nucl Med Commun 2004; 25:793–797.
Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001; 86:3507–3511.
Karam M, Gianoukas A, Feustel PJ, et al. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003; 24:489–495.
Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937–941.
Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 1999; 43:313–323.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
McDougall, I.R. (2006). Stunning Is Not a Problem. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_37
Download citation
DOI: https://doi.org/10.1007/978-1-59259-995-0_37
Publisher Name: Humana Press
Print ISBN: 978-1-58829-462-3
Online ISBN: 978-1-59259-995-0
eBook Packages: MedicineMedicine (R0)